BnH-015B / BnH Research - LARVOL DELTA

Positive modulation of NMDA receptors in the hippocampus ameliorates Alzheimer's disease phenotypes via IL-33/ST-2/OPN signaling in APP/PS1 mice. (Neuroscience 2025) - "Recently approved antiamyloid monoclonal antibodies—exemplified by lecanemab (Leqembi)—lower brain amyloid burden and produce moderately less cognitive decline versus placebo, but their safety profile reflects modality-specific liabilities, notably amyloid-related imaging abnormalities (ARIA) and infusion reactions; ARIA is recognized by the FDA as a class effect of antibodies targeting amyloid and is highlighted with a boxed warning on the Leqembi label. Finally, BnH-015B-treated mice exhibited significantly improved performance of hippocampus-dependent spatial learning and memory compared to vehicle-treated controls. These results suggest that Positive modulation of NMDA receptors in the hippocampus may rescue Hebbian synaptic plasticity and cognitive deficit, as well as amyloid-beta deposit via IL-33/ST-2/OPN signaling in the rodent Alzheimer's disease model."

Late-breaking abstract • Preclinical • Alzheimer's Disease • CNS Disorders • GRIN2B • IL33 • SPP1

BnH-015B Clinical Trial in Moderate Alzheimer's Disease (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: BnH Research | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

BnH-015B Clinical Trial in Moderate Alzheimer's Disease (clinicaltrials.gov) - P1 | N=92 | Not yet recruiting | Sponsor: BnH Research

New P1 trial • Alzheimer's Disease • CNS Disorders